Research programme: T lymphocyte modulators - PanVeraAlternative Names: T lymphocyte modulators research programme - PanVera
Latest Information Update: 21 Oct 2003
At a glance
- Originator PanVera LLC
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Immunosuppression
Most Recent Events
- 21 Oct 2003 No development reported - Preclinical for Immunosuppression in USA (unspecified route)
- 16 Apr 2003 PanVera LLC has been acquired by Invitrogen
- 21 Aug 2002 Aurora Biosciences Corporation has merged with PanVera Corporation to form PanVera LLC